Rethinking Routines in Multiple Sclerosis Management: What the Future Holds for DMTs and Cognitive Assessment StrategiesPremiere Date: Monday, March 8, 2021
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, March 8, 2022
Note: Credit Is No Longer Available
|Tanuja Chitnis, MD, FAAN
Professor of Neurology, Harvard Medical School
Director, Partners Pediatric Multiple Sclerosis Center
Massachusetts General Hospital
Director, Translational Neuroimmunology Research Center
Director, Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) Study
Partners Multiple Sclerosis Center
Brigham and Women's Hospital
|John DeLuca, PhD
Senior Vice President for Research
West Orange, NJ
Professor, Departments of Physical Medicine & Rehabilitation and Department of Neurology
Rutgers New Jersey Medical School
|Lauren B. Krupp, MD
Director, Multiple Sclerosis Comprehensive Care Center
NYU Langone Medical Center
Professor of Neurology
NYU Grossman School of Medicine
New York, NY
Multiple sclerosis (MS) is a chronic inflammatory and neurological disease that is the leading cause of disability in young and middle-aged people in the United States. The number of disease-modifying therapies (DMTs) available for treatment of MS has expanded in recent years, and it is imperative that neurologists and other health care professionals (HCPs) have up-to-date knowledge of clinical efficacy and safety of these therapeutic agents to inform individualized treatment decisions.
Cognitive impairment (CI) is common in patients with MS and contributes substantially to disability, loss of employment, and declines in quality of life, yet CI remains underrecognized. Clinicians need to be aware of recent recommendations for routine assessment and management of CI, deficits typical of MS. CI is increasingly being evaluated in clinical trials of MS therapies, and emerging evidence regarding cognitive effects of DMTs and the relationship between CI and other features of MS progression may have important implications for MS management.
This CME Outfitters webcast will feature an expert panel discussion that focuses on the efficacy and safety of recently approved DMTs, implementing cognitive assessment into routine monitoring for patients with MS, and emerging data on the effects of MS therapies on cognition.
At the end of this CE activity, participants should be able to:
- Apply clinical data on efficacy and safety of recently approved therapies to individualized treatment decisions for patients with MS.
- Incorporate cognitive assessment into routine monitoring for patients with MS.
- Evaluate emerging data on the effects of MS therapies on cognition.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Examine clinical data on efficacy and safety of recently approved therapies for individualized treatment plans for patients with MS.
- Describe how to incorporate cognitive assessment into routine monitoring for patients with MS.
- Evaluate emerging data on the effects of MS therapies on cognition.
Supported by an educational grant from Bristol Myers Squibb Company
Neurologists, PAs, nurse practitioners, nurses, pharmacists, and other HCPs involved in care of patients with MS
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs). Universal Activity Number: Enduring: JA0007185-0000-21-101-H01-P
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABPN MOC Credit:
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to PAs: PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chitnis has no disclosures to report.
Dr. DeLuca reports he received grants from Biogen. He is on the speakers bureau for Biogen. He is a consultant for the Celgene Corporation and Novartis.
Dr. Krupp reports she receives research support from Biogen (PI). She is a consultant for Eisai Inc.; Gerson Lehrman Group, Inc.; Janssen Pharmaceuticals, Inc.; Novartis; Roche; and Sanofi-Aventis.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Rachel Speer, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).